AB801 Potently & Selectively Inhibits AXL to Overcome Therapeutic Resistance
Time: 1:30 pm
day: Conference Day One
Details:
- Inhibiting both ligand-dependent and ligand-independent AXL signaling
- Attaining high selectivity and potency for optimal AXL inhibition
- Overcoming AXL-mediated resistance to standard-of-care therapies
